Drugs / MW-III
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01297400 | Mar 2022 → Dec 2026 expected | — | Skingenix, Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MW-III | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01297400 ↗ |
| Route | Topical | “Topical application, twice a day” NCT01297400 ↗ |